Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5541658 | 0.82 | CES2 (0.39) | TAAR1IDO1MPO | |
| SCHEMBL2139391 | 0.78 | TAAR1 (0.50) | TAAR1IDO1LMNAALDH1A1AOC3 | |
| SCHEMBL5536006 | 0.77 | TAAR1 (0.56) | TAAR1IDO1LMNAALDH1A1AOC3 | |
| SCHEMBL29734785 | 0.76 | TAAR1 (0.48) | TAAR1IDO1LMNAALDH1A1AOC3 | |
| SCHEMBL4262929 | 0.76 | TAAR1 (0.48) | TAAR1IDO1LMNAALDH1A1AOC3 | |
| SCHEMBL103401 | 0.76 | TAAR1 (0.48) | TAAR1IDO1LMNAALDH1A1AOC3 | |
| SCHEMBL1145372 | 0.72 | — | — | |
| SCHEMBL20465748 | 0.72 | — | — | |
| SCHEMBL29963524 | 0.72 | — | — | |
| SCHEMBL2962884 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122763-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2012-05-17 | — | — | US | claimed |
| EP-2150558-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AEterna Zentaris GmbH (DE) | 2010-02-10 | — | — | EP | claimed |
| US-20090170783-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2009-07-02 | — | — | US | claimed |
| WO-2008132153-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | ÆTERNA ZENTARIS GMBH (DE) | 2008-11-06 | — | — | WO | claimed |
| EP-1988098-A1 | Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors | AEterna Zentaris GmbH (DE) | 2008-11-05 | — | — | EP | claimed |
| EP-2160396-B1 | THIOCARBON-PROTECTING GROUPS FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES INC (US) | 2018-11-21 | — | — | EP | disclosed |
| EP-2476689-B1 | Thiocarbon-protecting groups for RNA synthesis | AGILENT TECHNOLOGIES INC (US) | 2015-10-21 | — | — | EP | disclosed |
| US-9067961-B2 | Thiocarbon-protecting groups for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| CN-101784556-B | Thiocarbon-protecting groups for rna synthesis | AGILENT TECHNOLOGIES INC | 2014-07-09 | — | — | CN | disclosed |
| US-8541462-B2 | Tetrahydrocarbazole derivatives as ligands of G-protein coupled receptors | AETERNA ZENTARIS GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-4820832-A | Process for preparing 3-unsubstituted cephalosporins and 1-carba(dethia)cephalosporins | ELI LILLY AND COMPANY (US) | 1989-04-11 | — | — | US | disclosed |
| EP-0299728-A2 | Carbonylation process for beta-lactam antibiotics | ELI LILLY AND COMPANY (US) | 1989-01-18 | — | — | EP | disclosed |
| US-4791106-A | 1-Carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1988-12-13 | — | — | US | disclosed |
| US-4778884-A | REACTING TRIFLUOROMETHYLSULFONYLOXY COMPOUND WITH LITHIUM HALIDE IN APROTIC POLAR SOLVENT | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 1988-10-18 | — | — | US | disclosed |
| EP-0232623-A1 | 1-Carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1987-08-19 | — | — | EP | disclosed |
| US-4673737-A | ANTIBIOTICS/ | HARVARD UNIVERSITY (US) | 1987-06-16 | — | — | US | disclosed |
| EP-0211540-A1 | Intermediates and process for antibiotics | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1987-02-25 | — | — | EP | disclosed |
| CN-86105247-A | Antibiotic intermediate and preparation method | — | 1987-02-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170783-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | GPR88, GPR34, GPR27 | TAAR1 205/4885IDO1 4311/4885LMNA 3715/4885 |
| US-20120122763-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | GPR88, GPR34, GPR27 | TAAR1 205/4885IDO1 4311/4885LMNA 3715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.